Market Cap
$1.3B
NKTR
NEKTAR THERAPEUTICS
$35.78 ▼ -5.14%
Prev close $37.72Market cap$1.3B
ConsensusStrong Buy
12-mo target$133.08 (+271.9%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on NKTR right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (83%)
Inst. Holders
1 funds
Inst. Value
$1.8K
Inst. Activity
1 buys / 0 sells
Insider Activity
$0.00 buy / $2.1M sell
Insider Net $
-$2.1M
Social Sentiment
67° Warm
SEC Reports
14
Price chart 30d -47.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 5, 2026 short_volume
Short Volume: NKTR — 59.0% short (0.4M / 0.7M)
Short: 408,457 | Exempt: 0 | TRF Vol: 692,522 | Short Ratio: 59.0% | Off-exchange volume (dark pool
Sep 30, 2026 Inst.
Farther Finance Advisors, LLC — DOUBLED
30 shares ($1.8K)
Sep 23, 2026 Insider
Ajer Jeffrey Robert was granted 2,000 shares
Director
Sep 23, 2026 Insider
Ajer Jeffrey Robert was granted 4,000 shares
Director
Sep 23, 2026 Insider
Aug 13, 2026 SEC Brainard Diana was granted 2,000 shares
Director
Nektar Therapeutics reported Q2 2026 EPS of -$1.23, a 39.6% beat vs consensus of -$2.04, on revenue of $10.1M (slightly
PRESS-RELEASE — Impact 7/10
Seven institutional investors accumulated $58.3M in NKTR during Q2 2026, with no sellers. State Street doubled its stake
INST-CLUSTER — Impact 5/10
The court issued a pretrial order setting a jury trial for September 8, 2026, in Nektar Therapeutics' patent case agains
COURT-RULING — Impact 4/10
Analyst ratings buy % -3.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
83% rate it Buy or better · 18 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 12, 2026 | UBS | INITIATE | Neutral | 55% |
| Oct 12, 2026 | Leerink Partners | INITIATE | Outperform | 49% |
| Oct 9, 2026 | BTIG | REITERATE | Buy | 53% |
| Oct 9, 2026 | Raymond James | INITIATE | Market Perform | 54% |
| Oct 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Sep 28, 2026 | BTIG | REITERATE | Buy | 53% |
| Sep 25, 2026 | BTIG | REITERATE | Buy | 53% |
| Sep 23, 2026 | Wedbush | MAINTAIN | Neutral | 57% |
| Sep 16, 2026 | BTIG | REITERATE | Buy | 53% |
| Sep 9, 2026 | BTIG | REITERATE | Buy | 53% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 8 | 3 | 0 | 0 | 83% | |
| Aug 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Jul 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Jun 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Apr 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% |
Price targets
Where 12 covering analysts think NKTR trades over the next 12 months.
$133.08 +271.9% upside Strong Buy
Current$35.78 Low$50.00 Median$150.00 High$192.00 12 analysts
$50.00$192.00
Analyst rating Buy· 1.6/5 as of Oct 19, 2026
Social media sentiment mood -26.7%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 3 bullish, 2 bearish, 2 mixed, 7 neutral · avg impact 4.5/10.
BULLISHPRESS-RELEASE7/10
Nektar Therapeutics reported Q2 2026 EPS of -$1.23, a 39.6% beat vs consensus of -$2.04, on revenue
Aug 13, 2026
BULLISHINST-CLUSTER5/10
Seven institutional investors accumulated $58.3M in NKTR during Q2 2026, with no sellers. State Stre
Aug 9, 2026
NEUTRALCOURT-RULING4/10
The court issued a pretrial order setting a jury trial for September 8, 2026, in Nektar Therapeutics
Aug 8, 2026
NEUTRALPRESS-RELEASE2/10
Nektar Therapeutics announced it will report Q2 2026 financial results on August 13, 2026. The filin
Jul 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 16, 2026
Clinical Trial
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Phase Phase 3 — TERMINATED
Oct 5, 2026
short_volume
Short Volume: NKTR — 59.0% short (0.4M / 0.7M)
Short: 408,457 | Exempt: 0 | TRF Vol: 692,522 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
other
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
Rezpegaldesleukin-associated improvements were detected as early as Week 2 and were significantly correlated with subsequent clinical response SAN FRA
Sep 30, 2026
short_interest_report
Short Interest: NKTR up 21% to 7.0M shares
Settlement 2026-09-30 | Days to cover: 3.76 | ≈20.41% of shares outstanding (est.)
Sep 25, 2026
other
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on September 18, 2026, the Organization and Com
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-2.07 | $-3.07–$-1.71 | -10.7% | +2.9% | 2↑ 0↓ | $0.0B | 15 |
| Next Q | $-2.76 | $-3.53–$-2.14 | -54.9% | -0.5% | 2↑ 0↓ | $0.0B | 15 |
| Current FY | $-8.08 | $-9.63–$-6.89 | 16.9% | +1.2% | 2↑ 0↓ | $0.0B | 15 |
| Next FY | $-10.50 | $-20.03–$-4.10 | -29.9% | +0.3% | 2↑ 0↓ | $0.1B | 15 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-2.069 | — |
| 7d ago | $-2.099 | +0.030 |
| 30d ago | $-2.131 | +0.061 |
| 60d ago | $-2.144 | +0.074 |
| 90d ago | $-2.152 | +0.082 |
Institutional ownership
Which big funds own NKTR (from quarterly 13F filings) and who is adding or trimming.
1 institutional holders with $1.8K total value (30 shares) as of 2026-Q3. Top holders: Farther. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top holders — 2026-Q3
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Farther Finance Advisors, LLC | 30 | $1.8K | 100.0% | DOUBLED +1400.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Farther Finance Advisors, LLC | DOUBLED | 2 | 30 | +1400.0% | $1.8K |
| BlackRock, Inc. | DOUBLED | 692,650 | 2,941,851 | +324.7% | $205.4M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | 1,197,055 | 1,496,849 | +25.0% | $104.5M |
| MORGAN STANLEY | ADD | 659,387 | 936,560 | +42.0% | $65.4M |
| STATE STREET CORP | DOUBLED | 244,727 | 909,679 | +271.7% | $63.5M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 346,795 | 881,306 | +154.1% | $61.5M |
| UBS Group AG | ADD | 320,172 | 428,400 | +33.8% | $29.9M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | 72,491 | 348,540 | +380.8% | $24.3M |
| NORTHERN TRUST CORP | DOUBLED | 78,598 | 308,531 | +292.5% | $21.5M |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 168,007 | 284,971 | +69.6% | $19.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 24 transactions. Net -$2.1M — $0.00 bought, $2.1M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Ajer Jeffrey Robert | Director | AWARD | 2,000 | — | — |
| Sep 23, 2026 | Ajer Jeffrey Robert | Director | AWARD | 4,000 | — | — |
| Sep 23, 2026 | Brainard Diana | Director | AWARD | 2,000 | — | — |
| Sep 23, 2026 | Brainard Diana | Director | AWARD | 4,000 | — | — |
| Sep 23, 2026 | CHESS ROBERT | Director | AWARD | 2,000 | — | — |
| Sep 23, 2026 | CHESS ROBERT | Director | AWARD | 4,000 | — | — |
| Sep 23, 2026 | GREER R SCOTT | Director | AWARD | 2,000 | — | — |
| Sep 23, 2026 | GREER R SCOTT | Director | AWARD | 4,000 | — | — |
| Sep 23, 2026 | WHITFIELD ROY A | Director | AWARD | 2,000 | — | — |
| Sep 23, 2026 | WHITFIELD ROY A | Director | AWARD | 4,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NKTR.
Shares short
6,968,325
Settlement Sep 30, 2026
Change vs prior
+21.5%
Semi-monthly cycle
Days to cover
3.8
At avg daily volume
Of shares outstanding
≈20.4%
Estimate — not % of float
All NKTR filing & press-release reports (14)
- PRESS-RELEASE reportAug 13, 2026
- INST-CLUSTER reportAug 9, 2026
- COURT-RULING reportAug 8, 2026
- PRESS-RELEASE reportJul 28, 2026
- INST-CLUSTER reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportMay 21, 2026
- 8-K reportMay 8, 2026
- 8-K reportMay 7, 2026
- DEFA14A reportApr 24, 2026
- 8-K reportApr 23, 2026
- 424B5 reportApr 23, 2026
- 424B5 reportApr 20, 2026
- 8-K reportApr 20, 2026